Geneva group lauds move on cheaper hep C drug

PETALING JAYA: Malaysia’s landmark decision to invoke a “government-use” licence to get access to affordable versions of a hepatitis C drug will have a major impact on global efforts to open up expensive treatments to more people, the Geneva-based Drugs for Neglected Diseases initiative (DNDi) said.

This should give 400,000 people living with hepatitis C in Malaysia access to sofosbuvir, DNDi executive director Dr Bernard Pécoul said in a statement on Wednesday.